National Cancer Institute (NCI) — Clinical Trial Pipeline

National Cancer Institute (NCI) has 45 registered trials in the index.

Trials (45)

Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1 · National Cancer Institute (NCI)
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors Phase 1 · National Cancer Institute (NCI)
Tanespimycin in Treating Patients With Stage III-IV Melanoma Phase 2 · National Cancer Institute (NCI)
Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer Phase 1 · National Cancer Institute (NCI)
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer Phase 2 · National Cancer Institute (NCI)
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) Phase 2 · National Cancer Institute (NCI)
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer Phase 3 · National Cancer Institute (NCI)
Imaging in MGUS, SMM and MM Phase 2 · National Cancer Institute (NCI)
Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity N/A · National Cancer Institute (NCI)
Nutrition Intervention Trials in Linxian Follow-up Study N/A · National Cancer Institute (NCI)
Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles N/A · National Cancer Institute (NCI)
Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors Phase 1 · National Cancer Institute (NCI)
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation Phase 1 · National Cancer Institute (NCI)
HGS-ETR2 to Treat Children With Solid Tumors Phase 1 · National Cancer Institute (NCI)
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer Phase 3 · National Cancer Institute (NCI)
CDDO to Treat Solid Tumors and Lymphomas Phase 1 · National Cancer Institute (NCI)
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Phase 2 · National Cancer Institute (NCI)
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial Phase 2 · National Cancer Institute (NCI)
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery Phase 2 · National Cancer Institute (NCI)
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1 · National Cancer Institute (NCI)
Evaluation of Food Effect on Pharmacokinetics of Vismodegib Phase 1/2 · National Cancer Institute (NCI)
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery Phase 2 · National Cancer Institute (NCI)
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) N/A · National Cancer Institute (NCI)
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer Phase 1 · National Cancer Institute (NCI)
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone Phase 3 · National Cancer Institute (NCI)
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma Phase 1 · National Cancer Institute (NCI)
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer Phase 2 · National Cancer Institute (NCI)
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer N/A · National Cancer Institute (NCI)
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors Phase 1 · National Cancer Institute (NCI)
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Phase 3 · National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma Phase 1/2 · National Cancer Institute (NCI)
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer Phase 2 · National Cancer Institute (NCI)
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma Phase 2 · National Cancer Institute (NCI)
Thyroid Abnormalities Associated With Exposure to Atmospheric Emissions of Radioactive Iodine N/A · National Cancer Institute (NCI)
Markers for Early Detection of Prostate Cancer N/A · National Cancer Institute (NCI)
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia Phase 1 · National Cancer Institute (NCI)
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Phase 2 · National Cancer Institute (NCI)
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery Phase 2 · National Cancer Institute (NCI)
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Phase 2 · National Cancer Institute (NCI)
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors Phase 1 · National Cancer Institute (NCI)
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer Phase 1/2 · National Cancer Institute (NCI)
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 2 · National Cancer Institute (NCI)
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Phase 1/2 · National Cancer Institute (NCI)
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer Phase 1 · National Cancer Institute (NCI)
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study N/A · National Cancer Institute (NCI)

Related landscapes

Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.